European advisory group backs Pfizer’s crisaborole for atopic dermatitis

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Pfizer’s (NYSE:PFE) Staquis (crisaborole) for the treatment of adults and pediatric patients at least two years old with mild or moderate atopic dermatitis with no more than 40% of body surface area affected.

A final decision from the European Commission usually takes ~60 days.

https://seekingalpha.com/news/3536796-european-advisory-group-backs-pfizers-crisaborole-for-atopic-dermatitis